SCHEMBL926027

SCHEMBL926027

CN(c1cc(Br)cnc1Cl)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 2/20 0.52
PSEN2 P49810 2/20 0.52
APH1B Q8WW43 2/20 0.52
NCSTN Q92542 2/20 0.52
APH1A Q96BI3 2/20 0.52
PSENEN Q9NZ42 2/20 0.52
PIK3CD O00329 1/20 0.48
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
CNR1 P21554 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
MMP9 P14780 2/20 0.41
MMP2 P08253 1/20 0.41
FFAR1 O14842 1/20 0.39
PIK3CA P42336 3/20 0.38
SIRT2 Q8IXJ6 2/20 0.38
MTOR P42345 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770120 0.86 PSEN1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL12274035 0.86 PIK3CD (0.62) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL24522222 0.80 EGFR (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL856141 0.77 PIK3CA (0.41) PIK3CDMAPTLMNAHTTNPSR1
SCHEMBL12276604 0.74 PIK3CD (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3103617 0.73 MMP9 (0.61) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1558035 0.72 CYP3A4 (0.48) PIK3CDNPSR1PIK3CAL3MBTL1KMT2A
SCHEMBL3114610 0.71 KDM4E (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL114959 0.71 PIK3CD (0.36) PIK3CDLMNAHTTNPSR1PIK3CA
SCHEMBL115237 0.70 PIK3CD (0.62) PIK3CDPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868188-B2 5-heteroaryl thiazoles and their use as PI3K inhibitors ASTRAZENECA AB (SE) 2011-01-11 US disclosed
EP-1841763-B1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2010-06-30 EP disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed
CN-101098869-A 5-heteroaryl thiazoles and their use as p13k inhibitors ASTRAZENECA AB (SE) 2008-01-02 CN disclosed
EP-1841763-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS AstraZeneca AB (SE) 2007-10-10 EP disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors MTOR, PIK3R5, PIK3CA PSEN1 2625/4885PSEN2 2434/4885APH1B 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.